In order to prevent spam,
this email address cannot be copied.
Researcher Profile - Philippe Marambaud Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Community: Researcher Profiles
Researcher Profile

RESEARCHER INFORMATION
First Name:Philippe
Last Name:Marambaud
Title:Associate Investigator
Advanced Degrees:Ph.D.
Affiliation:The Feinstein Institute for Medical Research - North-Shore LIJ
Department:Litwin-Zucker Research Center
Street Address 1:350 Community Drive
City:Manhasset
State/Province:NY
Zip/Postal Code:11030
Country/Territory:U.S.A.
Email Address: 
Disclosure:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 21 September 2011]
View all comments by Philippe Marambaud
Clinical Interests:
Tauopathies, Parkinson Disease, Aging Process, Alzheimer Disease, Prion Diseases, Polyglutamine Disorders (Huntington's, etc.)
Research Focus:
Animal Models, Signal transduction, Neurobiology, Genetics, Molecular and Cell biology, A-beta PP/A-beta
Work Sector(s):
Research institute
Web Sites:
Lab: http://www.feinsteininstitute.org/cs/Satellite?c=eHA_Content_C&cid=1228244190494&pagename=Feinstein%2FCentral_Template
Top Papers
1. Chapuis J, Vingtdeux V, Campagne F, Davies P, Marambaud P*. Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet. 2011 May 15;20(10):2026-36. PMID: 21357679

2. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P*. CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med. 2011 May 24. In press. PMID: 21629967

3. Vingtdeux V, Davies P, Dickson DW, Marambaud P*. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011 Mar;121(3):337-49. PMID: 20957377

4. Vingtdeux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P*. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J. 2011 Jan;25(1):219-31. PMID: 20852062

5. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P*. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010 Mar 19;285(12):9100-13.

6. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P*. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008 Jun 27;133(7):1149-61.

7. Marambaud P*, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005, 280: 37377-82.

8. Marambaud P and Robakis NK. Genetic and Molecular Aspects of Alzheimer’s disease Shed Light on New Mechanisms of Transcriptional Regulation. Genes, Brain and Behavior 2005, 4, 134-146.

9. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP-binding transcriptional repressor produced by the PS1/γ-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003, 114, 635-645 (Commentary by Rao and Finkbeiner, Cell 2003, 114: 533-535; and by Fortini M., Nature 2003, 425: 565-566).

10. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002 Apr 15;21(8):1948-56.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad